Therapeutic Outcome of Second Primary Malignancies in Patients with Well-Differentiated Thyroid Cancer

Table 3

Clinical features of 200 cases of well-differentiated thyroid cancer with second primary malignancy (SPM) as breast cancer or other cancers.

Clinical characteristic	All patients	Breast cancer	Other cancers	value
Patient number	200	45 (22.5%)	155 (77.5%)
Gender (female)	139 (69.5%)	45 (100.0%)	94 (60.6%)	0.0001
Age at diagnosis (year)	51.6 ± 13.2	47.1 ± 10.2	52.9 ± 13.7	0.0099
Mean tumor size (cm)	2.4 ± 1.5	2.2 ± 1.2	2.4 ± 1.6	0.5271
Thyroid operative method				0.4470
Total thyroidectomy	155 (77.5%)	33 (73.3%)	122 (78.7%)
Less than total thyroidectomy	45 (22.5%)	12 (26.7%)	33 (21.3%)
TNM stage				0.0518
Stage I	101 (50.5%)	26 (57.8%)	75 (48.4%)
Stage II	27 (13.5%)	9 (20.0%)	18 (11.6%)
Stage III	25 (12.5%)	6 (13.3%)	19 (12.3%)
Stage IV	47 (23.5%)	4 (8.9%)	43 (27.7%)
Nonremission	48 (24.0%)	5 (11.1%)	43 (27.7%)	0.0215
Follow-up period (year)	9.2 ± 6.6	9.6 ± 6.0	9.1 ± 6.7	0.6467
Postoperative ^131I accumulative dose (mCi)	166.3 ± 258.2	95.1 ± 102.1	187.0 ± 284.8	0.0357
^131I dose ≥ 30 mCi	167 (83.5%)	40 (88.9%)	127 (81.9%)	0.2686
Radiation therapy	24 (12.0%)	1 (2.2%)	23 (14.8%)	0.0219
Time to metachronous SPM diagnosis (year) [range]	7.7 ± 5.7 [0.5–22.2]	7.5 ± 5.2 [0.6–21.2]	7.8 ± 5.8 [0.5–22.2]	0.8190
Multifocality	50 (25.0%)	10 (22.2%)	40 (25.8%)	0.6250
Mortality due to thyroid cancer	18 (9.0%)	1 (2.2%)	17 (11.0%)	0.0711
Overall mortality	74 (37.0%)	6 (13.3%)	68 (43.9%)	0.0002

Papillary, follicular, and Hürthle’s cell thyroid cancer.